This article provides commentary on the semiconductor industry's trends and challenges, without reporting on any specific new development or company action.
Enhertu's potential approval as a post-neoadjuvant treatment for HER2-positive early breast cancer could significantly improve patient outcomes by reducing recurrence risk. This would establish a new standard of care, addressing a critical unmet need for patients with residual disease after initial therapy and potentially preventing progression to metastatic disease.
Enhertu reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 in the DESTINY-Breast05 trial.
The three-year invasive disease-free survival rate was 92.4% with Enhertu versus 83.7% with T-DM1.
The FDA has set a Prescription Drug User Fee Act (PDUFA) date for the third quarter of 2026.
Enhertu's potential US approval sets a strong precedent for regulatory pathways in key APAC markets like Japan, China, and South Korea, where HER2-positive breast cancer incidence is significant. Daiichi Sankyo, a co-developer, has a strong presence in Japan, potentially accelerating local market access. APAC healthcare providers will closely monitor its adoption, influencing treatment guidelines and market access strategies for similar innovative therapies across the region. This could intensify competition for existing HER2 therapies from companies like Roche in these markets.
The three-year invasive disease-free survival rate was 92.4% with Enhertu versus 83.7% with T-DM1.
The FDA has set a Prescription Drug User Fee Act (PDUFA) date for the third quarter of 2026.
Sign in to save notes on signals.
Sign In